More Racura Oncology Ltd news
Racura Oncology LtdASX: RAC

RC220 Human Ethics Approvals Received in Hong Kong

Jul 9, 2025 at 11:28 PM EDT · Issued by Racura Oncology Ltd

Filed with ASX · Jul 9, 2025 at 11:28 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/rc220-human-ethics-approvals-received-in-hong-kong

Racura Oncology Ltd on 6ix

Earlier from Racura Oncology

  • First Patient Safely Combine Dosed in Phase 1 RC220 TrialJun 18, 2025
  • First Patient Dosed Safely in RC220 Phase 1 TrialApr 30, 2025
  • March 2025 Quarterly Activity Report and Appendix 4CApr 22, 2025
  • Enrolment Opened at Second Site for RC220 Phase 1 TrialApr 21, 2025
  • RC220 Phase 1 Trial Opens for Patient EnrolmentApr 2, 2025

Later from Racura Oncology

  • June 2025 Quarterly Activity Report and Appendix 4CJul 22, 2025
  • Appendix 4E & Annual ReportAug 26, 2025
  • First Hong Kong Site Activated for RC220 TrialSep 1, 2025
  • Race Breakthrough Composition of Matter IP DiscoverySep 15, 2025
  • RC220 IND Approval from Korean MFDSSep 23, 2025
All Racura Oncology news releases↗

Follow Racura Oncology into a list and get an email when it puts out news.

Follow Racura Oncology
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer